AWH vs. ICCC, ABIO, OCX, CDIO, VNRX, TRIB, BMRA, TKNO, UG, and JUPW
Should you be buying Aspira Women's Health stock or one of its competitors? The main competitors of Aspira Women's Health include ImmuCell (ICCC), ARCA biopharma (ABIO), OncoCyte (OCX), Cardio Diagnostics (CDIO), VolitionRx (VNRX), Trinity Biotech (TRIB), Biomerica (BMRA), Alpha Teknova (TKNO), United-Guardian (UG), and Jupiter Wellness (JUPW). These companies are all part of the "medical" sector.
Aspira Women's Health (NASDAQ:AWH) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, Aspira Women's Health had 5 more articles in the media than ImmuCell. MarketBeat recorded 9 mentions for Aspira Women's Health and 4 mentions for ImmuCell. Aspira Women's Health's average media sentiment score of 0.77 beat ImmuCell's score of 0.22 indicating that Aspira Women's Health is being referred to more favorably in the media.
12.2% of Aspira Women's Health shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 4.3% of Aspira Women's Health shares are owned by insiders. Comparatively, 6.3% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ImmuCell has a net margin of -33.05% compared to Aspira Women's Health's net margin of -176.74%. ImmuCell's return on equity of -21.79% beat Aspira Women's Health's return on equity.
ImmuCell received 108 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 28.89% of users gave Aspira Women's Health an outperform vote.
ImmuCell has higher revenue and earnings than Aspira Women's Health. ImmuCell is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
Aspira Women's Health presently has a consensus price target of $4.45, indicating a potential upside of 48.33%. Given Aspira Women's Health's higher probable upside, analysts clearly believe Aspira Women's Health is more favorable than ImmuCell.
Aspira Women's Health has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Summary
ImmuCell beats Aspira Women's Health on 10 of the 17 factors compared between the two stocks.
Get Aspira Women's Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for AWH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AWH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aspira Women's Health Competitors List
Related Companies and Tools
